- 295 private and 87 public cord blood banks listed
- European Hematology Association (EHA) validated benefits of cord blood stem cell transplantation in 2011
- Mergers, acquisitions and collaborations are commonplace within cord blood stem cell market
The market for cord blood stem cells is expanding globally, according to a new report available from companiesandmarkets.com. Scientific advances have increased the number of regenerative medicine applications using cord blood stem cells, and research has shown that stem cells taken from the individual being treated are most likely to result in a successful regenerative procedure.
Cord Blood Stem Cells – A Global Market Overview
http://www.companiesandmarkets.com/Market-Report/cord-blood-stem-cells-a-global-market-overview-701576.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2
Cord blood stem cells are syringed from the placenta through the umbilical cord of newborn babies, after the cord has been removed. Stem cells within the blood can be used for the treatment of various genetic conditions and blood cell proliferation disorders; therefore an increasing number of parents are opting to store cord blood to ensure stem cell availability should medical treatment be required. For congenital heart defects, cord blood is believed to be the most effective treatment option.
After extraction, stored blood can also be made available in public cord banks. This is more widely supported than private storage, which has attracted controversy. Specific concerns around private cord blood storage are focused on the actual likelihood of an individual needing to use stored cord blood, and the undetermined level of success associated with treatment.
Several diseases are currently treated using cord blood: cerebral palsy; various leukemias and myelodysplastic syndromes; lymphoma; inherited red cell abnormalities; blood cell proliferation disorders; bone marrow, and other cancers.
Over 80 companies are profiled within the cord blood stem cells research report, including key players such as: BioCell, Cellsafe International Group, Cell Care Pty Ltd, Cord Bank, Cord Life Ltd, Cordlife Group, CryoCord, Cryosite Ltd, CyGenics Ltd, Golden MediTech Company, Jeevan Stem Cell Bank, Kaneka Corporation, Life Cord, Reliance Life Sciences, Singapore Cord Blood Bank, Ltd., Stem Life, and Sydney Cord Blood Bank.
Published in October 2011, the 282 page study examines the cord blood stem cell market for the period 2006-2015, split geographically: Asia-Pacific, Europe, North America and Rest of the World. Further country-specific analysis is included for 21 countries.
Report Details:
http://www.companiesandmarkets.com/Market-Report/cord-blood-stem-cells-a-global-market-overview-701576.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2
Contacts:
Companies & Markets
Mike King
Press Office
enquiries@companiesandmarkets.com
London
(UK): +44 (0) 203 086 8600
